ABSTRACT
SOURCE CITATION: Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022;386:531-43. 34910859.
Subject(s)
COVID-19 , Vaccines , Adult , COVID-19/prevention & control , COVID-19 Vaccines , Humans , SARS-CoV-2 , United States/epidemiologyABSTRACT
SOURCE CITATION: Borobia AM, Carcas AJ, Perez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398:121-30. 34181880.
Subject(s)
COVID-19 , Vaccines , BNT162 Vaccine , COVID-19 Vaccines , Humans , Immunity , Immunogenicity, Vaccine , SARS-CoV-2ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic has become a major public health crisis. The diagnostic and containment efforts for the disease have presented significant challenges for the global health-care community. In this brief report, we provide perspective on the potential use of salivary specimens for detection and serial monitoring of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on current literature. Oral health-care providers are at an elevated risk of exposure to COVID-19 due to their proximity to nasopharynx of patients, and the practice involving the use of aerosol-generating equipment. Here, we summarize the general guidelines for oral health-care specialists for prevention of nosocomial transmission of COVID-19, and provide specific recommendations for clinical care management.
Subject(s)
Betacoronavirus/isolation & purification , Coronavirus Infections/prevention & control , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Occupational Exposure/prevention & control , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Practice Patterns, Dentists' , Saliva/virology , Anti-Infective Agents, Local/administration & dosage , COVID-19 , Coronavirus Infections/diagnosis , Coronavirus Infections/transmission , Dentists , Guidelines as Topic , Humans , Infection Control/methods , Mouthwashes , Personal Protective Equipment/supply & distribution , Pneumonia, Viral/diagnosis , Pneumonia, Viral/transmission , Povidone-Iodine/administration & dosage , Respiratory Protective Devices , SARS-CoV-2 , United States/epidemiologyABSTRACT
Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a long time. Therefore, the repurposing of existing drugs for new indications is needed. In this article, we argue for the potential benefits of using doxycycline with either hydroxycholoroquine or other putative agents for COVID-19 treatment, as doxycycline has antiviral and anti-inflammatory activities by dampening the cytokine storm and to prevent lung damage.